https://www.selleckchem.com/products/nu7026.html Background Despite the emergence of app evaluation tools, there remains no well-defined process receptive to diverse local needs, rigorous standards, and current content. The need for such a process to assist in the implementation of app evaluation across all medical fields is evident. Such a process has the potential to increase engagement of stakeholders and catalyze interest and engagement with present-day app evaluation models. To address this need, we developed, and pilot tested the Technology Evaluation and Assessment Criteria for Health apps (TEACH-apps). Objective To address this need, we developed, and pilot tested the Technology Evaluation and Assessment Criteria for Health apps (TEACH-apps). Methods Tailoring a well-known implementation framework, Replicating Effective Programs, we present a new process to approach the challenges faced in implementing app evaluation tools today. As a culmination of our experience implementing this process and feedback from stakeholders, we present the four-part process may lead to the selection of more culturally appropriate and clinically relevant tools in healthcare.Immunosuppression and immunomodulation are valuable therapeutic approaches for managing neuroimmunological diseases. In times of the Coronavirus disease 2019 (COVID-19) pandemic, clinicians must deal with the question of whether immunotherapy should currently be initiated or discontinued in neurological patients. Uncertainty exists especially because different national medical associations publish different recommendations on the extent to which immunotherapies must be continued, monitored, or possibly switched during the current pandemic. Based on the most recently available data both about the novel coronavirus and the approved immunotherapies for neurological diseases, we provide an updated overview that includes current treatment strategies and the associated COVID-19 risk, but also the potential of immuno